Clinical trials: Neoadjuvant Radiotherapy
Retroperitoneal Soft Tissue Sarcoma
Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)
Local control rates in patients with retroperitoneal soft tissue sarcoma (RSTS) remain disappointing even after gross total resection, mainly because wide margins are not achievable in the majority of patients.
- Trial name
- NCT01566123
- Testing
- Neoadjuvant intensity-modulated radiation therapy (IMRT), intraoperative radiation therapy (IORT)
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- University Hospital Heidelberg
Adenocarcinoma of Head of Pancreas
Neoadjuvant Folfirinox Followed by Capecitabine and Limited Field Radiation for Localized Pancreatic Head Adenocarcinoma
This study is for subjects with adenocarcinoma of the pancreas. The purpose of this research study is to determine the safety and effectiveness of modified Folfirinox and radiation therapy as treatment for adenocarcinoma (cancer)…
- Trial name
- NCT01677988
- Testing
- Neo-adjuvant Chemotherapy, Chemoradiation, Surgical Resection
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Medical University of South Carolina
Soft Tissue Sarcoma
Hypofractionated vs Conventional Fractionated RT in Soft Tissue Sarcomas
This research study is designed to find out if radiation therapy treatment prior to surgery is safe and effective to treat soft tissue sarcomas.
- Trial name
- NCT05109494
- Testing
- Conventional Fractionated, Hypofractionated
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer
The study seeks to establish the safety of neoadjuvant aromatase inhibitor with: DPX-Survivac, DPX-Survivac plus radiation, or DPX-Survivac with cyclophosphamide in stage I to III HR+HER2- breast cancer.
- Trial name
- NCT04895761
- Testing
- DPX-Survivac, Letrozole 2.5mg, Cyclophosphamide 50mg
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Providence Health & Services
Rectal Cancer
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
A combination of chemotherapy and radiation is often used to treat rectal cancer patients before surgery in an effort to shrink the tumor and make it easier to remove as well as to help increase the chances of sphincter-sparing…
- Trial name
- NCT00250835
- Testing
- Chemotherapy, Celecoxib, and Radiation
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- New Mexico Cancer Research Alliance
Gastric Cancer
SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer
Neoadjuvant chemotherapy or chemoradiotherapy has become the standard neoadjuvant regimen for locally advanced G/GEJ cancer and has been recommended by a series of treatment guidelines.
- Trial name
- NCT06266871
- Testing
- SOX+Tislelizumab+LDRT
- Volunteers
- 64 people
- Sponsor
- West China Hospital
Pancreatic Cancer
Efficacy of Neoadjuvant Chemoradiation for Potentially Resectable Pancreas Cancer
This study is to determine the efficacy of bevacizumab and gemcitabine in combination with radiation therapy in the preoperative treatment of potentially-resectable subjects with pancreatic cancer.
- Trial name
- NCT00557492
- Testing
- Avastin (bevacizumab), Gemzar (Gemcitabine), external beam radiotherapy
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Amer Zureikat
Rectal Cancer
TaTME Versus Open Intersphincteric Resection After Neoadjuvant Concurrent Chemoradiotherapy.
The two surgical options for lower 1/3 rectal cancer is APR and sphincter sparing procedures. Intersphincteric resection is procedure to treat very low rectal cancer within 2 cm from the dentate line to avoid permanent…
- Trial name
- TaTME (NCT01836926)
- Testing
- Open intersphincteric resection, transanal minimally invasive intersphincteric resection
- Where
- 2 sites in Egypt
- Volunteers
- 110 people
- Sponsor
- Osama Mohammad Ali ElDamshety
High-Risk Cancer, Locally Advanced Breast Cancer
Three Fraction Radiation to Induce Immuno-Oncologic Response
Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple negative and HER2-positive breast…
- Trial name
- TRIO (NCT03978663)
- Testing
- Neoadjuvant radiotherapy
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Rectal Neoplasms, Drug Therapy
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer
To evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation therapy and XELOX chemotherapy in the patients with locally advanced…
- Conditions
- Rectal Neoplasms, Drug Therapy, Radiation
- Trial name
- NCT03484221
- Testing
- FOLFOXIRI, Short-Course Radiation Therapy(5Gy*5), XELOX
- Where
- China
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Head and Neck Cancer
Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC
This study compares the efficacy of neoadjuvant low-dose radiotherapy plus targeted-immunotherapy versus targeted-immunotherapy alone in resectable HNSCC patients.
- Trial name
- NCT06804850
- Testing
- Tislelizumab, Afatinib, Low dose radiotherapy
- Sponsor
- West China Hospital
Early Stage Breast Carcinoma
Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy
Radiation therapy after surgery to remove breast cancer improves control of the breast cancer. Standard therapy after breast conservation surgery is five to six weeks of radiation to the entire breast.
- Trial name
- SIGNAL 2 (NCT02212860)
- Testing
- Stereotactic Body Radiation Then Surgery
- Where
- Canada
- Volunteers
- 139 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Local Advanced Rectal Cancer, PD-1 Inhibitor
Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial
This is a randomized, controlled clinical trial based on prior exploratory findings, designed to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with tafolecimab(an anti-PCSK9 inhibitor) and sintilimab…
- Conditions
- Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT
- Trial name
- NCT07686796
- Testing
- Short-course radiotherapy, CAPOX (oxaliplatin/capecitabine), Sintilimab
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Guangdong Provincial People's Hospital
Thymic Carcinoma
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
The aims of this study are to verify the feasibility, effectiveness, and safety of the combination of enrolizumab and radiotherapy for neoadjuvant treatment for locally advanced thymic carcinoma, and to provide recommendations…
- Trial name
- NCT06019468
- Testing
- Envolizumab combined with radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Cervical Cancer
Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00462397
- Testing
- carboplatin, cisplatin, paclitaxel
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University College London Hospitals
Rectal Cancer
A Study Comparing Adjuvant Chemotherapy Versus Observation for Patients With Rectal Adenocarcinoma After Neoadjuvant Chemo-Radiotherapy Treatment.
Surgery is the most indicated curative treatment for rectal cancer when disease is diagnosed early, however local recurrence risk increases when the disease is diagnosed at advanced stage.T1-2 tumors have a recurrence rate lower…
- Trial name
- NCT01941979
- Testing
- 5-FU, Capecitabine, Oxaliplatin, Leucovorin.
- Where
- Brazil
- Volunteers
- 309 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Breast Cancer, Breast Cancer Stage II
Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer
This study will evaluate the immune-priming effects of stereotactic body radiation therapy (SBRT) regimen coupled with two injections of pembrolizumab in high-risk primary breast carcinoma prior to neoadjuvant chemotherapy.
- Conditions
- Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Invasive
- Trial name
- BRINK (NCT07188246)
- Testing
- Radiation, Pembrolizumab (KEYTRUDA®)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cervical Cancer
Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy drugs before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00039338
- Testing
- conventional surgery, neoadjuvant chemotherapy, brachytherapy
- Where
- 24 sites in Austria, Belgium and 6 more
- Volunteers
- 686 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Sarcoma
Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as SU5416 may stop the growth of cancer by stopping blood flow to the tumor.
- Trial name
- NCT00023738
- Testing
- filgrastim, dacarbazine, doxorubicin hydrochloride
- Where
- 226 sites in United States, Canada
- Sponsor
- Radiation Therapy Oncology Group
NSCLC (Advanced Non-small Cell Lung Cancer), Post Surgical
Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC
Patients with stage III non-small-cell lung cancer (NSCLC) who receive neoadjuvant chemoimmunotherapy may achieve good response in the primary tumor but still have residual nodal disease after surgery (ypTanyN⁺M0), which is…
- Trial name
- NCT07353476
- Testing
- radiotherapy, PD -1/PD-L1 monoclonal antibody
- Volunteers
- 38 people
- Sponsor
- Shanghai Zhongshan Hospital